Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Liminal BioSciences Inc. PFSCF


Primary Symbol: LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Bullboard Posts
Comment by Staghorn69on Mar 08, 2019 9:05am
221 Views
Post# 29460133

RE:Catalysts in lead up to AGM

RE:Catalysts in lead up to AGM
sah1 wrote: In addition to recent PRs on the engagement of Lazard and the additional financing from TV, I am expecting to see the following developments in the lead up to the AGM in mid-May:

- completion of the batch runs necessary to demonstrate conformance with CMC (quality control)requirements established by the FDA 

-FDA approval of the IND for the pivotal phase 3 trials on Alstrom 

-announcement of a partnership deal on Pg CD providing upfront cash inthe 10s of millions of $$. 


Clearly the Pg deal is dependent on the batch run meeting CMC requirements which in turn will give the market confidence that the FDA will approve Pg after the revised BLA is filed in mid year. If these catalysts come to fruition, they will spark a dramatic turnaround in the sp. If not, we will continue to languish in the doldrums.


I cannot believe how bad this management team pooched the Pg launch... Un. Believable. Now we are praying for a deal in the tens of millions.. far cry from the old story. Damage is done.
Bullboard Posts